▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #2533 by analyst upside · 2026-09-27
PRCT
PROCEPT BioRobotics Corporation
Healthcare · Market Cap $979M · P/E 0x
ANALYST PRICE TARGET
+25.8%
implied upside to consensus target
Current Price $17.2
Consensus Target $21.64
Bull Target $28.0
Bear Target $16.0
Analysts Covering 11
ANALYST CONSENSUS - HOLD
Strong Buy
1
Buy
2
Hold
7
Sell
1
52-Week Low $16.66
52-Week High $38.11
YTD Return -44.1%
FUNDAMENTALS
Market Cap $979M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-1.95
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $337M
Profit Margin -32.5%
52-WEEK RANGE
52-Week Low $16.66
52-Week High $38.11
Current Price $17.2
Bear Target $16.0
Bull Target $28.0
● Now $17.2 ● Target $21.64
TRADING DATA
Avg Volume 1.4M
YTD Return -44.1%
Analyst Count 11
Consensus Hold
Upside to Target +25.8%
Last Updated 2026-09-27

ANALYST SUMMARY

PROCEPT BioRobotics Corporation (PRCT) is currently trading at $17.2 with a Wall Street consensus price target of $21.64, implying potential upside of 25.8% over the next 12 months. 11 analysts currently cover PRCT, with a consensus rating of Hold - 27% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $28.0, while the most cautious has a target of $16.0.

PRCT operates in the Healthcare sector with a market capitalisation of $979M. The stock is down 44.1% year-to-date and is currently trading near the lower end of its 52-week range of $16.66 – $38.11.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RIGL +30.8%
Rigel Pharmaceuticals, Inc.
$900M · P/E 2.9x · Buy
ABUS +11.3%
Arbutus Biopharma Corporation
$961M · P/E 6.1x · Buy
INMD +13.4%
InMode Ltd.
$821M · P/E 11.8x · Hold
BVS +27.4%
Bioventus Inc.
$943M · P/E 17.7x · Buy
TBPH +3.7%
Theravance Biopharma, Inc.
$884M · P/E 16.4x · Hold

RECENT ANALYST CALLS

Upgrade/downgrade history for PRCT, with each firm's 90-day track record across all stocks we track. See full firm rankings →

TD Cowen - Reiterated
Buy → Buy 2026-08-05 Building track record
Piper Sandler - Reiterated
Overweight → Overweight 2026-08-05 14% win rate (7 calls)
Evercore ISI Group - Reiterated
Outperform → Outperform 2026-08-05 Building track record
William Blair ↓ Downgrade
Outperform → Market Perform 2026-08-05 44% win rate (9 calls)
Truist Securities ↓ Downgrade
Buy → Hold 2026-07-06 Building track record
Evercore ISI Group ● Initiated
Outperform 2026-06-24 Building track record
Leerink Partners ↓ Downgrade
Outperform → Market Perform 2026-06-11 29% win rate (7 calls)
Piper Sandler reit
Overweight → Overweight 2026-04-30 14% win rate (7 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
37
out of 100
Coverage depth
19/30
Consensus clarity
16/30
Vote unanimity
0/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →